According to a new study published in the Yale Journal of Biology and Medicine, dried cannabis flower consumption significantly reduces symptoms of depression and works much faster than pharmaceutical antidepressants
“Israeli med-tech company Syqe Medical has conducted the first clinical trial to demonstrate that extremely low and precise doses of inhaled THC – the principal psychoactive constituent of cannabis – can effectively relieve pain, while avoiding the common side effects associated with cannabis use.”
With cannabis still designated as a Schedule I controlled substance, many researchers are restricted in scope by federal regulations governing the psychoactive chemical THC. “There’s a lot of evidence that could be gathered and it’s just not being done. We desperately need research,” said Arthur Fougner, president of the Medical Society of the State of New York.
In today’s legal, recreational cannabis market, two factors - price and THC content - tend to influence what the consumer decides to buy, but recent research has begun to show that THC content is a poor indicator of product quality and potency. As more scientific research occurs and the general consumer becomes more educated, there are several new factors that may ultimately drive cannabis purchasing decisions.
“New results from a Colorado study indicate that inhaling cannabis concentrates, or 'dabbing,' doesn’t affect a person’s balance or sense of being 'high' any more than smoking the flower form of the drug, despite causing high levels of THC in the blood. The findings could lead to eventual changes in how law enforcement uses roadside sobriety tests to determine whether a driver is under the influence of cannabis."